Table 3.
Multivariate analysis
| Outcome | Relative Risk (95% CI) | P-value |
|---|---|---|
| TRMb | ||
| Acute GVHD | ||
| No | 1.00a | |
| Yes | 2.42 (1.18 – 4.96) | 0.016 |
| Relapsec | ||
| Type of transplant | ||
| First allogeneic | 1.00a | |
| Planned autologous+allogeneic | 0.59 (0.36 – 0.98) | 0.043 |
| Chronic GVHD | ||
| No | 1.00a | |
| Limited | 0.35 (0.13 – 0.93) | 0.035 |
| Extensive | 0.58 (0.29 – 1.19) | 0.14 |
| Event-free survival (RR of relapse/death)d | ||
| Type of transplant | ||
| First allogeneic | 1.00a | |
| Planned autologous+allogeneic | 0.57 (0.38 – 0.86) | 0.008 |
| Chronic GVHD | ||
| No | 1.00a | |
| Limited | 0.40 (0.19 – 0.90) | 0.027 |
| Extensive | 0.81 (0.47 – 1.41) | 0.56 |
| Overall survival (RR of death)e | ||
| Acute GVHD | ||
| First allogeneic | ||
| No | 1.00a | |
| Yes | 0.90 (0.48 – 1.70) | 0.75 |
| Planned autologous+allogeneic | ||
| No | 1.00a | |
| Yes | 3.52 (1.67 – 7.45) | 0.001 |
a
Reference group
GVHD impact (yes vs. no) on outcomes where not significant summarized below:
| bLimited chronic GVHD | RR=0.65 (0.17–2.47) | p=0.53 |
| bExtensive chronic GVHD | RR=1.50 (0.61–3.70) | p=0.37 |
| cAcute GVHD | RR=0.79 (0.47–1.36) | p=0.40 |
| dAcute GVHD | RR=1.10 (0.72–1.68) | p=0.66 |
| eLimited cGVHD | RR=0.45 (0.18–1.13) | p=0.09 |
| eExtensive cGVHD | RR=1.18 (0.66–2.10) | p=0.59 |
| eTest interaction: p(first allogeneic=planned autologous+allogeneic) = 0.005 | ||